Clinical Trial Update: Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes [Phase 3]

View source ↗

Summary

Enlicitide Decanoate (MK-0616) is being studied as an oral PCSK9 inhibitor in the Phase 3 CORALreef Outcomes cardiovascular outcomes trial (MK-0616-015); the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arteriosclerosis
• Hypercholesterolemia

Drugs mentioned

• Enlicitide Decanoate (Enlicitide Decanoate)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Arteriosclerosis, Hypercholesterolaemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING